Metabolism

Items 171-180 of 252

per page
Set Descending Direction
  1. Erythroferrone (human) ELISA Kit
    AG-45B-0014
    AG-45B-0014-KI0196 wells
    CHF 610.00
    Figure: Specific quantitation of APRIL in human serum.
Method: Serum from a healthy patient is left untreated or treated with 1µg/ml of the APRIL receptor, TACI (human):Fc (human) (Prod. No. AG-40B-0079). APRIL levels were measured us
  2. Erythroferrone (human) Matched Pair Detection Set
    AG-46B-0012
    AG-46B-0012-KI011 Set
    CHF 750.00
    Erythroferrone (human) Matched Pair Detection Set
  3. FABP1 (human) (rec.) (His)
    AG-40A-0039T
    AG-40A-0039T-C05050 µg
    CHF 350.00
    Replaces AG-40A-0039
  4. FABP3 (human) (rec.) (untagged)
    AG-40B-6002
    AG-40B-6002-C05050 µg
    CHF 350.00
  5. FABP4 (human) (rec.) (His)
    AG-40A-0035
    AG-40A-0035-C05050 µg
    CHF 250.00
  6. Fc (human):CD137L, Soluble (human) (rec.)
    AG-40B-0173
    AG-40B-0173-C01010 µg
    CHF 265.00
    AG-40B-0173-30103 x 10 µg
    CHF 530.00
    Fc (human):CD137L, Soluble (human) (rec.) (AG-40B-0173) binds to human CD137. Method: CD137 (human):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of Fc (human):CD137L, Soluble (human) (AG-40B-
  7. Fc (human):FGL1 (human) (rec.)
    AG-40B-0184
    AG-40B-0184-C01010 µg
    CHF 240.00
    AG-40B-0184-30103 x 10 µg
    CHF 480.00
    AG-40B-0184-C100100 µg
    CHF 1'140.00
  8. Fc (human):FNDC4 (rec.)
    AG-40B-0213
    AG-40B-0213-C05050 µg
    CHF 330.00
    AG-40B-0213-30503 x 50 µg
    CHF 660.00
  9. Fc (LALA-PG)-KIH (human):GDF15 (human) (rec.)
    AG-40B-0253
    AG-40B-0253-C05050 µg
    CHF 440.00
    NEW Fc (LALA-PG)-KIH (human):GDF15 (human) (rec.)
  10. Fc (LALA-PG)-KIH (human):Irisin (monomeric) (rec.)
    AG-40B-0246
    AG-40B-0246-C05050 µg
    CHF 440.00

    Replaces AG-40B-0115

    Fc (LALA-PG)-KIH (human):Irisin (monomeric) (rec.)

Items 171-180 of 252

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.